cancer screening
The firm said its DNA methylation testing technology could be applied to dozens of cancers and potentially some non-cancer chronic diseases.
Recent meeting presentations have offered a first look at the company's targeted methylation approach and the test's high sensitivity in early-stage cancers.
The method, called GEMINI, improved detection of both overall cancer and the earliest-stage cancers when added to the firm's existing platform.
Myriad Genetics, Onsite Women's Health Partner to ID Women With High Breast Cancer Risk
The program makes Myriad's hereditary breast cancer and risk assessment tools available to Onsite's pool of over 400,000 patients.
The company said it expects to launch a first version of its residual cancer test, OncoDetect, by the end of this year, while ongoing studies explore newer technology.
Apr 21, 2023